Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 4078266 | The rheumatoid wrist after resection of the distal ulna. | 1985 Nov | Thirty-three wrists in 25 patients with rheumatoid arthritis were followed for an average of 3.8 years after resection of the distal ulna. These patients, including those who had adjunctive implantation of a silicone rubber cap, manifested considerable amounts of carpal collapse, carpal translocation, rotational change of the wrist, and radial shift of the ulna. The progression of these complications was unpredictable. Four patients required revision. Three of these four patients had no articular contact between the lunate and radius on their preoperative x-ray film. Excision of less than 20 mm of the distal ulna is an acceptable range of resection. In 15% of the wrists, an osseous carpal stabilizer was seen on the preoperative x-ray film as a reliable radiographic indicator of radiocarpal stability. Another 12% of patients developed a bony carpal stabilizer during the postoperative period. | |
| 6810769 | Fate of the thiomalate part after intramuscular administration of aurothiomalate in rheuma | 1982 Aug | The excretory fate and plasma level of thiomalate were studied after intramuscular administration of auro-14C-thiomalate to 3 patients with rheumatoid arthritis. The gold and the thiomalate parts separated in vivo, and the free thiomalate was excreted in the urine, rapidly at first and then slowly. After one day about 60% of the 14C-label had been recovered in the urine. The plasma level also declined rapidly. The results are in complete agreement with those previously described in animal experiments. | |
| 6236013 | Enumeration of T-lymphocytes and T-lymphocyte subsets in rheumatoid arthritis using monocl | 1982 Sep | The number of T-lymphocytes and T-lymphocyte subsets was measured in peripheral blood of 51 patients with rheumatoid arthritis. T-lymphocytes were counted by E-rosette tests and by the immunogold staining method with OKT3.PAN monoclonal antibody. Helper and suppressor T-lymphocytes were determined by the immunogold staining method with OKT4.IND and OKT8.SUP monoclonal antibody. The relative and absolute numbers of T-lymphocytes and helper T-lymphocytes in peripheral blood of patients with RA did not differ significantly from those in the blood of healthy subjects. However, the relative and absolute numbers of suppressor T-cells were significantly lower in patients with RA than in healthy subjects. The decrease of suppressor T-cells in the blood of patients with RA dit not correlate with the activity of the disease nor the presence of the rheumatoid factor. | |
| 1262888 | Vertebrobasilar artery insufficiency in rheumatoid atlantoaxial subluxation. | 1976 Feb | Cervical myelopathy has become commonly recognized as a complication of rheumatoid atlantoaxial subluxation. A small group of patients with atlantoaxial subluxation may have intermittent symptoms associated with change of head position and which are due to vertebral artery compression. Two such cases are reported, one with necropsy findings of infarction in the area supplied by the vertebrobasilar system. The pathogenesis of the symptomatology and infarction is discussed. | |
| 720443 | Studies on a new acute phase protein. I. Immunocytochemical demonstration of the origin. | 1978 | Synovial fluid of patients with rheumatoid arthritis or traumatic arthritis contains an antigen which is thermostable to boiling temperature and insoluble in ethanol. The antigen was not found in sera of healthy subjects but it is present in numerous sera of patients with different inflammatory diseases. The partial purification of the antigen and the production of specific antisera are described. Immunofluorescent staining of tissue sections and blood smears indicates, that the antigen is a cytoplasmic protein of polymorphonuclear leucocytes. Monocytes contain the antigen to a lower degree, it was not found in eosinophils and lymphocytes. In addition, the influence of different fixing agents and of other pretreatment on the pattern of the cell fluorescence was studied. We propose to designate the antigen as thermostable granulocyte antigen (TSGA). | |
| 485579 | Resumption of treatment with penicillamine after proteinuria. | 1979 Jun | Penicillamine has been successfully reintroduced and continued for a minimum of 13 months in 5 patients who developed proteinuria during the first course of the drug. The daily maintenance dose during the second course was 150--250 mg taken midway between 2 meals. Proteinuria did not recur; no significant excretion of fibrin degradation products occurred; complement, urea, creatinine, and serum albumin remained within normal limits. Urine microscopy showed no abnormality. | |
| 342992 | [Experiences with the use of sodium diclofenac (Voltaren) in rheumatic diseases]. | 1978 Feb 4 | 150 mg/day sodic diclofenac was found particularly active in subjects with diathetic rheumatism and arthrosis. Excellent general and gastrointestinal tolerance was noted after prolonged administration and in aged subjects with cardiac damage. A protracted therapeutic effect was obtained, especially in cases of diathetic rheumatism. | |
| 588456 | Herpetiform pemphigus induced by penicillamine. | 1977 Oct | A patient with arthritis is described who developed a dermatitis herpetiformis-like rash after 8 months of D-penicillamine therapy and which cleared soon after the drug was discontinued. The histopathological findings were compatible with a diagnosis of pemphigus, showing intra-epidermal vesicles and spongiosis but no acantholysis. Intercellular antibody was detected by indirect immunofluorescence at the onset of the eruption (titre 1 in 160) and also found in serum taken prior to penicillamine treatment (titre 1 in 20). It is now well known that D-penicillamine can induce pemphigus. The findings reported here suggest the possibility that the patient was predisposed to develop the eruption before the drug was given. | |
| 4017308 | Superoxide dismutases in polymorphonuclear leukocytes from patients with ankylosing spondy | 1985 Apr | The activity of cyanide-sensitive and cyanide-insensitive superoxide dismutase (CNs- and CNi-SOD) was measured in polymorphonuclear neutrophils isolated from the blood of patients with ankylosing spondylitis (A.S.) or adults with rheumatoid arthritis (R.A.). Our purpose was to detect alterations in the protecting activity of these enzymes that might cause rheumatic lesions secondary to superoxide anion generation in the inflammatory loci. There was no difference in total SOD activity (CNs + CNi) in either A.S. or R.A. when compared to the control group. In contrast, CNi-SOD activity decreased in R.A. and A.S. and CNs-SOD activity rose significantly in A.S. only. None of the changes observed in SOD activity correlated with patient's age, erythrocyte sedimentation rate, clinical evolution of the disease or the drug doses administered. It is concluded that the reduced activity of CNi-SOD might be partly responsible for the reduced protection of the joints against oxygen-free radicals in patients with A.S. or R.A. Other factors however appear to have greater effects on the clinical evolution of these diseases. | |
| 334474 | A comparative study of flurbiprofen and indomethacin in rheumatoid arthritis. | 1977 | A double-blind, crossover study was carried out in 30 patients with active, classical or definite rheumatoid arthritis to compare the effect of 200 mg flurbiprofen per day with that of 100 mg indomethacin per day. Patients received, at random, each drug for a period of 2 weeks separated by a weeks' wash-out period on placebo. Assessments were made before the start of the trial and at weekly intervals of pain, morning stiffness, grip strength, articular index, walking time, and finger joint size. Patients' preference for any particular treatment period was recorded at the end of the trial. Laboratory investigations were carried out before and during the trial. Both drugs shows statistically significant improvement over baseline assessments, although there was little difference between the two active treatment periods. More patients preferred the treatment period with flurbiprofen, and this was probably related to the fewer side-effects which were reported with this drug. | |
| 7043711 | Thymopoietin in rheumatoid arthritis. | 1982 May | In a controlled study involving 36 patients, thymopoietin was shown to be more effective than levamisole and as effective as penicillamine in improving the clinical status of patients with rheumatoid arthritis. There were small reductions in erythrocyte sedimentation rate and IgG which did not achieve statistical significance. Rheumatoid factor titre did not change. Although its mechanism of action is almost certainly related to its immunomodulatory properties it does not seem to be the same as that of levamisole. | |
| 6982718 | IgM and IgG anti-F(ab')2 antibodies in rheumatoid arthritis and systemic lupus erythematos | 1982 Nov | Radioimmunoassays for anti-F(ab')2 antibodies, which feature the use of goat anti-human Fc antibody for correcting potentiation of IgM anti-F(ab')2 antibody titers by endogenous IgM anti-Fc antibodies (rheumatoid factors), are described. Individuals with classic rheumatoid arthritis had significantly more IgM anti-F(ab')2 antibody (P less than 0.001) and IgG anti-F(ab')2 antibody (P = 0.05) than did individuals with systemic lupus erythematosus or normal volunteers. There is some similarity in patterns of isotype distribution of anti-F(ab')2 antibodies and rheumatoid factors. | |
| 1078778 | The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue d | 1975 Jan | Absolute numbers of B (IgG-, IgM-, and IgA-staining) and T lymphocytes (sheep erythrocyte rosette-forming cells) were determined in patients with systemic lupus erythematosus and other connective tissue diseases in cyclophosphamide-treated and noncyclophosphamide-treated patients and in control subjects. In patients receiving cyclophosphamide, all three types of immunoglobulin-staining varieties of circulating B lymphocytes were significantly decreased. At the same time the circulating T lymphocytes were also significantly reduced. In patients with scleroderma treated with therapeutic doses of cyclophosphamide and studied sequentially, the reduction in B lymphocytes occurred first, with eventual depletion of both cell types. In 2 patients, an early rebound increase in T cells occurred followed by a marked reduction. These data indicate that the immunosuppressive effects of cyclophosphamide may be associated with a reduction in both cell types. | |
| 1092274 | Macrophage-lymphocyte clustering in rheumatoid arthritis. | 1975 Feb | The cells in synovial fluid from patients with rheumatoid arthritis contain a small percentage of macrophages. Such macrophages were isolated and cultured alone and with homologous and heterologous lymphocytes for 24 hours, in an attempt to identify possible contact between living lymphocytes and macrophages. Such contact was found, with clustering of lymphocytes around macrophages, and was particularly well shown by scanning electron microscopy. | |
| 6342962 | Efficacy and tolerance of a novel precision-dose formulation of indomethacin: double-blind | 1983 | Two short-term, double-blind, multi-centre studies, one in rheumatoid arthritis and the other in osteoarthritis, were carried out to investigate the efficacy and tolerance of two formulations of the new osmotic delivery system containing sodium indomethacin trihydrate ('Osmosin') compared with conventional indomethacin capsules and placebo. Both formulations contained the equivalent of 85 mg indomethacin. 'Osmosin' was designed to deliver drug in solution at a constant rate of 7 mg per hour, the other formulation at 9 mg per hour. The results indicated that 'Osmosin' administered once or twice daily was at least as effective in reducing disease symptoms as 25 mg indomethacin capsules 3-times daily. In addition, the combined incidence of gastro-intestinal side-effects reported in the two studies was significantly lower with 'Osmosin' than with the other active drug groups. The possible contribution of this novel drug delivery system towards patient compliance as a result of less frequent administration and fewer digestive system side-effects is discussed. | |
| 7027433 | Investigation of blood platelets in synovial fluid from patients with rheumatoid arthritis | 1981 | Synovial fluid (SF) aspirated from inflamed knee joints from each of 13 patients with adult rheumatoid arthritis (RA) was mixed with ACD in the ratio SF/ACD=9:1 with subsequent addition of an equivalent amount of an edta-tris buffer. The mixture was centrifuged to obtain a platelet-rich supernatant. The platelets were washed three times and counted. The same procedure was performed with SF from non-inflamed knee-joints from 3 patients with osteoarthrosis (OA). Direct immunofluorescence (IF) studies were performed with aliquots of platelet suspensions from each SF. In most RA specimens observed under the microscope before separation of platelets, a few small platelet aggregates were observed and platelets were seen in contact with lymphocytes. In all instances, the platelet count appeared to be positively correlated to the total number of white blood cells. In the OA specimens, relatively few platelets were detected, a few lymphocytes were seen in contact with platelets, but no platelet aggregates or correlation between platelets and white blood cell counts were found. Results of the IF studies of RA specimens provide evidence that IgG, IgM and C3 are located on the platelet surface. On the surface of OA platelets, however, only IgG and C3 were detected. Identical staining results were found with washed peripheral platelets from 3 of the RA and 1 of the OA patients. Neither medical treatment nor Waaler serology influenced the staining results. In inflamed SF from RA patients, both IgG aggregates, immune complexes, collagen, and prostaglandins can induce a platelet release reaction with liberation of vasoactive compounds, chemotactic substances and enzymes which can destroy connective tissue, cartilage and bone structures. Interpretations and the significance of the different results are discussed. | |
| 7363495 | Spontaneous and X-ray induced chromosomal aberrations in selected connective tissue diseas | 1980 Feb | Chromosome studies were performed on peripheral blood lymphocytes of 28 patients with connective tissue disease (6 with progressive systemic sclerosis, 6 with systemic lupus erythematosus, 6 with anti-nuclear antibody positive rheumatoid arthritis, 6 with anti-nuclear antibody negative rheumatoid arthritis, and 4 with mixed connective tissue disease) and on 17 controls to determine the frequency of spontaneous as well as X-ray (75 rads) induced aberrations. The mean spontaneous chromosomal aberration frequency for the 28 patients (9.1%) was significantly (P = 0.038) greater than that of controls (6.4%). When patients were categorized into specific clinically designated connective tissue disease subdivisions for comparison with the controls, only X-irradiated cells from the progressive systemic sclerosis group displayed significantly elevated levels of total chromosomal aberrations over those of the control group. The X-irradiated lymphocytes from these patients had an average of 23.6% aberrations per patient, while those of the control group showed an average of 14.9% per patient (P less than 0.05). | |
| 6400539 | Pyoderma gangrenosum. | 1983 Jul | Since its description 50 years ago, pyoderma gangrenosum has continued to capture the attention and imagination of all those who see its dramatic presentation. Clinical observation still provides the only reliable diagnosis. As investigative techniques increase, more and more intriguing immunologic abnormalities associated with this disorder are discovered, but understanding of the pathogenesis remains elusive. It is now recognized as an independent condition as well as a co-condition with many systemic disorders. Many new treatment options are available, allowing much individualization of treatment. For now, pyoderma gangrenosum remains an impressive, relatively easily recognized, but poorly understood disease. | |
| 157095 | Autoantibodies and the spectrum of Sjögren's syndrome. | 1979 Aug | In studies reported recently, the sera of patients with Sjögren's syndrome were found to contain precipitating antibodies to nuclear antigens that can be identified by immunodiffusion analysis. These precipitating autoantibodies have been termed SS-A and SS-B antibodies. We show that identification of these autoantibodies helped in establishing the diagnosis of Sjögren's syndrome in 12 of 30 patients in whom the diagnosis had not been considered at the time of the physician's initial examination. The reasons for this were related to lack of spontaneous complaints of keratoconjunctivitis sicca and xerostomia and prominence of symptoms associated with arthritis, myalgia, pulmonary fibrosis, and cardiac disease. This study re-emphasizes the importance of multisystem disease in Sjögren's syndrome and shows that specific serologic assays for autoantibodies aided in diagnosis. | |
| 6315936 | Monocyte dependent excited oxygen radical generation in rheumatoid arthritis: inhibition b | 1983 Oct | A chemiluminescent assay was used to measure generation of excited oxygen species by peripheral blood monocytes obtained from normal controls (NC) and patients with rheumatoid arthritis (RA). Whole peripheral blood mononuclear cells (PBMC) and adherent cells (AdhC) from RA patients showed a significantly higher chemiluminescent response to opsonized zymosan at certain observation times than cells from NC. There was no significant difference however in response to stimulation by calcium ionophore (CI). Gold sodium thiomalate (GSTM) significantly inhibited the peak response of fresh PBMC and AdhC (from both RA and NC) to zymosan and CI. GSTM inhibited only the peak response of fresh cells to zymosan; by contrast cells cultured with GSTM for 72 h showed inhibition at all time periods. The effect of GSTM was dependent on dosage and duration of incubation with cells. The addition of GSTM after zymosan stimulation did not inhibit chemiluminescence. GSTM appears to act upon cellular events following membrane activation which culminates in the generation of excited oxidative species. These results suggest a mechanism of action for GSTM in RA by inhibition of monocyte and macrophage dependent generation of oxy radicals and related excited oxygen species. |